| Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel Journal of neuroinflammation 19 (1), 45, 2022 | 111 | 2022 |
| Comorbidity, physical and mental health among cancer patients and survivors: an Australian population‐based study HS Ng, D Roder, B Koczwara, A Vitry Asia‐Pacific Journal of Clinical Oncology 14 (2), e181-e192, 2018 | 80 | 2018 |
| Patterns of comorbidities in women with breast cancer: a Canadian population-based study HS Ng, A Vitry, B Koczwara, D Roder, ML McBride Cancer Causes & Control 30, 931-941, 2019 | 75 | 2019 |
| Multiple sclerosis incidence: a systematic review of change over time by geographical region J Lane, HS Ng, C Poyser, RM Lucas, H Tremlett Multiple Sclerosis and Related Disorders 63, 103932, 2022 | 68 | 2022 |
| Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study HS Ng, B Koczwara, D Roder, A Vitry Prostate cancer and prostatic diseases 21 (3), 403-410, 2018 | 50 | 2018 |
| Assessment of the therapeutic value of new medicines marketed in Australia AI Vitry, NH Shin, P Vitre Journal of pharmaceutical policy and practice 6, 1-6, 2013 | 43 | 2013 |
| Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review HS Ng, CL Rosenbult, H Tremlett Expert Opinion on Drug Safety 19 (9), 1069-1094, 2020 | 35 | 2020 |
| Comorbidities in Australian women with hormone‐dependent breast cancer: a population‐based analysis HS Ng, B Koczwara, DM Roder, T Niyonsenga, AI Vitry Medical Journal of Australia 208 (1), 24-28, 2018 | 30 | 2018 |
| Changes in the prevalence of comorbidity in the Australian population with cancer, 2007–2014 HS Ng, B Koczwara, D Roder, A Vitry Cancer Epidemiology 54, 56-62, 2018 | 22 | 2018 |
| Polypharmacy and multiple sclerosis: A population-based study A Chertcoff, HS Ng, F Zhu, Y Zhao, H Tremlett Multiple Sclerosis Journal, 13524585221122207, 2022 | 21 | 2022 |
| Women's health in multiple sclerosis: a scoping review L Ross, HS Ng, J O'Mahony, MP Amato, JA Cohen, MP Harnegie, ... Frontiers in neurology 12, 812147, 2022 | 20 | 2022 |
| Disease-modifying drugs for multiple sclerosis and association with survival HS Ng, F Zhu, E Kingwell, S Yao, O Ekuma, C Evans, JD Fisk, RA Marrie, ... Neurology: Neuroimmunology & Neuroinflammation 9 (5), e200005, 2022 | 19 | 2022 |
| Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study HS Ng, B Koczwara, D Roder, T Niyonsenga, A Vitry Journal of comorbidity 8 (1), 16-24, 2018 | 19 | 2018 |
| Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis F Calocer, HS Ng, F Zhu, Y Zhao, O Dejardin, E Leray, G Defer, C Evans, ... Multiple Sclerosis Journal 29 (3), 466-470, 2023 | 14 | 2023 |
| Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting HS Ng, F Zhu, E Kingwell, Y Zhao, S Yao, O Ekuma, LW Svenson, ... Expert Review of Neurotherapeutics 21 (1), 131-140, 2021 | 13 | 2021 |
| Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis G Liang, J Chai, HS Ng, H Tremlett Multiple Sclerosis and Related Disorders, 102566, 2020 | 13 | 2020 |
| Disease-modifying drug uptake and health service use in the ageing MS population HS Ng, J Graf, F Zhu, E Kingwell, O Aktas, P Albrecht, HP Hartung, ... Frontiers in immunology 12, 794075, 2022 | 12 | 2022 |
| Disease-modifying drugs for multiple sclerosis and subsequent health service use HS Ng, F Zhu, E Kingwell, Y Zhao, S Yao, O Ekuma, LW Svenson, ... Multiple Sclerosis Journal 28 (4), 583-596, 2022 | 10 | 2022 |
| Patterns of health service utilisation among the Australian population with cancer compared with the general population HS Ng, B Koczwara, D Roder, RJ Chan, A Vitry Australian Health Review 44 (3), 470-479, 2019 | 10 | 2019 |
| Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study HS Ng, F Zhu, Y Zhao, S Yao, X Lu, O Ekuma, C Evans, JD Fisk, ... Neurology 102 (3), e208006, 2024 | 8 | 2024 |